Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The granulocyte-macrophage colony-stimulating factor receptor alpha subunit (GM-CSFRα), also known as CSF2RA or CD116, is a critical component of the heterodimeric GM-CSF receptor complex. This receptor mediates the biological effects of granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that regulates the production, differentiation, and function of granulocytes and macrophages. It consists of an alpha chain (GM-CSFRα), responsible for ligand binding, and a beta chain (βc), shared with IL-3 and IL-5 receptors, responsible for signal transduction. GM-CSF first binds to GM-CSFRα with low affinity, followed by recruitment of βc to form a high-affinity complex, leading to activation of downstream signaling pathways like JAK/STAT, MAPK, and PI3K.
GM-CSF binding and subsequent activation of JAK/STAT, MAPK, and PI3K pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Granulocyte-Macrophage Colony-Stimulating Factor Receptor Alpha Subunit (None).